Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027MIAMI, Dec. 18, 2025 ...
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied ...
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, ...
SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...
SIOUX FALLS, S.D., April 13, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
The Staff Accounting Bulletin (SAB) 121 rule was introduced by the SEC in March 2022 as part of its efforts to regulate cryptocurrency custody. It required financial institutions to list any crypto ...
SAB has launched a new, more modern logo. Its CEO believes better times lie ahead for South Africa thanks to a growing youthful population. A merged Heineken and Distell group could bring more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback